BR112014032938A2 - uso de peptídeos de glp-1 de longa ação - Google Patents

uso de peptídeos de glp-1 de longa ação

Info

Publication number
BR112014032938A2
BR112014032938A2 BR112014032938A BR112014032938A BR112014032938A2 BR 112014032938 A2 BR112014032938 A2 BR 112014032938A2 BR 112014032938 A BR112014032938 A BR 112014032938A BR 112014032938 A BR112014032938 A BR 112014032938A BR 112014032938 A2 BR112014032938 A2 BR 112014032938A2
Authority
BR
Brazil
Prior art keywords
peptides
long
acting glp
glp
acting
Prior art date
Application number
BR112014032938A
Other languages
English (en)
Portuguese (pt)
Inventor
Bjørn Jensen Christine
Frederik Rasmussen Mads
Zdravkovic Milan
Kristensen Peter
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR112014032938A2 publication Critical patent/BR112014032938A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112014032938A 2012-07-01 2013-06-21 uso de peptídeos de glp-1 de longa ação BR112014032938A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12174535 2012-07-01
US201261694837P 2012-08-30 2012-08-30
US201261708162P 2012-10-01 2012-10-01
EP12186781 2012-10-01
PCT/EP2013/063004 WO2014005858A1 (en) 2012-07-01 2013-06-21 Use of long-acting glp-1 peptides

Publications (1)

Publication Number Publication Date
BR112014032938A2 true BR112014032938A2 (pt) 2017-08-01

Family

ID=65858459

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032938A BR112014032938A2 (pt) 2012-07-01 2013-06-21 uso de peptídeos de glp-1 de longa ação

Country Status (17)

Country Link
US (2) US9764003B2 (enExample)
EP (3) EP2866825B1 (enExample)
JP (1) JP6059802B2 (enExample)
AU (3) AU2013286177B2 (enExample)
BR (1) BR112014032938A2 (enExample)
CA (1) CA2877056A1 (enExample)
DK (1) DK2866825T3 (enExample)
ES (2) ES3041720T3 (enExample)
HR (2) HRP20251088T1 (enExample)
HU (1) HUE049152T2 (enExample)
MX (3) MX366405B (enExample)
PL (2) PL3689365T3 (enExample)
PT (1) PT2866825T (enExample)
RS (2) RS60432B1 (enExample)
RU (2) RU2657573C2 (enExample)
SI (1) SI2866825T1 (enExample)
WO (1) WO2014005858A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60321B1 (sr) 2010-12-16 2020-07-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
PL2827885T3 (pl) 2012-03-22 2019-01-31 Novo Nordisk A/S Kompozycje peptydów GLP-1 i ich otrzymywanie
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
ES3041720T3 (en) 2012-07-01 2025-11-14 Novo Nordisk As Use of long-acting glp-1 peptides
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
US10543843B2 (en) * 2014-10-16 2020-01-28 Yanmar Co., Ltd. Work vehicle
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
DE102017106216A1 (de) * 2017-03-22 2018-09-27 Amw Gmbh Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
MX2020001525A (es) 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
IL322969A (en) 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
GB201720187D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
CN111683676B (zh) 2018-02-02 2024-06-18 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
US20210162013A1 (en) * 2018-08-03 2021-06-03 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
AU2020229349A1 (en) * 2019-02-26 2021-10-14 Twist Bioscience Corporation Variant nucleic acid libraries for GLP1 receptor
MX2022004779A (es) * 2019-11-06 2022-06-14 Novo Nordisk As Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia.
CN119060161A (zh) * 2019-12-30 2024-12-03 甘李药业股份有限公司 长效glp-1化合物
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations
CN112768087A (zh) * 2020-12-23 2021-05-07 吉林大学 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途
EP4359074A4 (en) * 2021-06-24 2025-06-04 Gila Therapeutics, Inc. METHODS AND KITS FOR INDUCTING SATOURAGE AND TREATMENT OF METABOLIC DISEASES
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
AU2022349020A1 (en) 2021-09-27 2024-05-09 Terns Pharmaceuticals, Inc. Benzimidazole carboxylic acids as glp-1r agonists
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
IL312672A (en) 2021-11-10 2024-07-01 I2O Therapeutics Inc Ionic liquid compositions
CN115850438B (zh) * 2021-12-28 2023-05-12 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
JP2025508812A (ja) 2022-02-23 2025-04-10 ターンズ・ファーマシューティカルズ・インコーポレイテッド Ｇｌｐ－１ｒアゴニストとしての化合物
US20230374096A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
KR20250141711A (ko) 2022-12-30 2025-09-29 알지파마 에이에스 경구 투여되는 폴리펩타이드 치료제의 전신 생체이용률을 증가시키는 조성물 및 방법
KR20250166323A (ko) 2023-04-07 2025-11-27 테른스 파마슈티칼스, 인크. 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합
WO2025024455A1 (en) 2023-07-24 2025-01-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for delivery of therapeutic peptides
WO2025165146A1 (ko) * 2024-01-29 2025-08-07 주식회사 티온랩테라퓨틱스 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
CN118845644B (zh) * 2024-09-27 2025-01-17 杭州信海医药科技有限公司 一种司美格鲁肽注射液的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
CZ300837B6 (cs) 1996-08-30 2009-08-26 Novo Nordisk A/S Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
CN1882356B (zh) 2003-11-20 2015-02-25 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
CN106137952B (zh) 2004-11-12 2020-11-17 诺和诺德公司 促胰岛素肽的稳定制剂
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
BRPI0709964A2 (pt) 2006-04-14 2011-08-02 Mannkind Corp formulações farmacêuticas contendo peptìdeo glucagon do tipo 1 (glp-1)
CA2677852A1 (en) 2007-03-20 2008-09-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
JP5476304B2 (ja) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
EP2190873B1 (en) 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
JP2012511586A (ja) 2008-12-10 2012-05-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 医薬組成物
CA2752437C (en) * 2009-02-13 2017-07-11 Boehringer Ingelheim International Gmbh Antidiabetic medications
WO2011080103A1 (en) * 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
RS60321B1 (sr) 2010-12-16 2020-07-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
CN103906528A (zh) * 2011-06-24 2014-07-02 安米林药品有限责任公司 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法
ES3041720T3 (en) 2012-07-01 2025-11-14 Novo Nordisk As Use of long-acting glp-1 peptides

Also Published As

Publication number Publication date
RU2018117557A3 (enExample) 2021-08-20
RU2015101826A (ru) 2016-08-20
US20150190474A1 (en) 2015-07-09
HRP20251088T1 (hr) 2025-11-07
PL3689365T3 (pl) 2025-11-12
RS67258B1 (sr) 2025-10-31
EP3689365B1 (en) 2025-08-06
AU2020202573B2 (en) 2023-04-20
AU2018202504B2 (en) 2020-05-07
HRP20200889T1 (hr) 2020-09-04
AU2020202573A1 (en) 2020-05-07
US10335462B2 (en) 2019-07-02
HUE049152T2 (hu) 2020-09-28
EP4406593A3 (en) 2024-10-23
EP2866825A1 (en) 2015-05-06
MX376058B (es) 2025-03-07
AU2013286177B2 (en) 2018-04-26
EP3689365A1 (en) 2020-08-05
ES2796839T3 (es) 2020-11-30
ES3041720T3 (en) 2025-11-14
SI2866825T1 (sl) 2020-07-31
US9764003B2 (en) 2017-09-19
MX2019008148A (es) 2019-09-05
PT2866825T (pt) 2020-07-15
EP4406593A2 (en) 2024-07-31
AU2018202504A1 (en) 2018-05-10
PL2866825T3 (pl) 2021-02-22
DK2866825T3 (da) 2020-06-08
JP2015522573A (ja) 2015-08-06
RU2018117557A (ru) 2019-03-22
CA2877056A1 (en) 2014-01-09
JP6059802B2 (ja) 2017-01-11
EP3689365C0 (en) 2025-08-06
AU2013286177A1 (en) 2015-01-15
MX366405B (es) 2019-07-08
WO2014005858A1 (en) 2014-01-09
RS60432B1 (sr) 2020-07-31
MX2020010693A (es) 2020-11-06
EP2866825B1 (en) 2020-04-08
RU2657573C2 (ru) 2018-06-14
US20180085435A1 (en) 2018-03-29
MX2014014946A (es) 2015-04-08

Similar Documents

Publication Publication Date Title
BR112014032938A2 (pt) uso de peptídeos de glp-1 de longa ação
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112015026325A2 (pt) dosagem oral de compostos glp-1
CL2013003688A1 (es) Peptido coagonista del receptor de glucagon/glp-1; conjugado de dicho peptido; composicion farmacéutica; uso del peptido para tratar una enfermedad seleccionada del grupo de síndrome metabólico, diabetes, obesidad, esteatosis hepática y una enfermedad neurodegenerativa.
MX2014002159A (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
CL2013000716A1 (es) Un profarmaco o una sal del mismo que comprende un conjugado de exendina-conector; procedimiento de preparacion de dicho profarmaco; compuestos intermediarios; composicion farmaceutica que lo comprende, util para mejorar el control glucemico en pacientes con diabetes de tipo 2.
MX371187B (es) Péptidos terapéuticos.
EA201590058A1 (ru) Аналоги глюкагона
BR112012017150A2 (pt) formulação de anticorpo e regimes terapêuticos.
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
CL2015001699A1 (es) Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c.
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
UA118558C2 (uk) Пептидна сполука
CL2014001254A1 (es) Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes.
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
MX362456B (es) Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
MX382516B (es) Composiciones y metodos para absorcion transmucosa.
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
PL2707015T5 (pl) Liksysenatyd jako terapia uzupełniająca do insuliny bazalnej w cukrzycy typu 2
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
TR201100150A2 (tr) Suda çözünür dozaj formları
EA201490041A1 (ru) Пластырь, содержащий диклофенак и тиоколхикозид
TR201100148A2 (tr) Stabil akarboz förmülasyonları.
GEP201706742B (en) Glycogen-based water solubility enhancers

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]